文献速递妇科

β受体阻滞剂使用与晚期卵巢癌生存的多变量分析

Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-03-25

本研究为回顾性队列研究,纳入534例IIIC/IV期上皮性卵巢癌减灭术患者,分析β受体阻滞剂使用与生存的关系。结果显示,使用β受体阻滞剂者中位总生存期29个月,未使用者35个月(HR=1.52,p=0.007)。调整混杂因素后,β受体阻滞剂使用仍与死亡风险增加相关(校正HR=1.57,p=0.006)。

要点

  • β受体阻滞剂使用与晚期卵巢癌患者更差的总生存期相关。
  • 使用β受体阻滞剂者中位总生存期29个月,未使用者35个月。
  • 调整混杂因素后,β受体阻滞剂使用仍与死亡风险增加独立相关。

核心结论

  • 在晚期卵巢癌减灭术患者中,使用β受体阻滞剂与更差的总生存期和更高的死亡风险相关。

研究设计与样本

  • 回顾性队列研究,纳入534例接受初次或间歇性肿瘤细胞减灭术的IIIC/IV期上皮性卵巢癌女性。

主要发现

  • 使用β受体阻滞剂者中位总生存期29个月,未使用者35个月(HR=1.52,p=0.007)。
  • 调整人口学、临床、组织病理学因素及常用合并用药后,β受体阻滞剂使用仍与死亡风险增加相关(校正HR=1.57,p=0.006)。
  • 使用β受体阻滞剂者中90%为心脏选择性β受体阻滞剂。

关键数值与推荐

  • β受体阻滞剂使用定义为肿瘤细胞减灭术时正在使用。
  • 研究纳入IIIC期和IV期上皮性卵巢癌患者。

临床怎么用

  • 对于接受减灭术的晚期卵巢癌患者,使用β受体阻滞剂可能提示预后更差。

局限性

  • 回顾性研究设计可能引入选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this study, we sought to evaluate the relationship between survival and beta blocker use in both the primary and interval debulking setting while adjusting for frequently co-administered medications. METHODS: We performed a retrospective cohort study reviewing charts of women who underwent primary or interval cytoreduction for stage IIIC and IV epithelial ovarian cancer. The exposure of interest was beta-blocker use identified at the time of cytoreduction. The outcomes of interest were PFS and OS. We collected demographic/prognostic variables and information about use of aspirin, metformin, and statins. We used the Kaplan-Meier method and Cox proportional hazards models in survival analyses. RESULTS: 534 women who underwent surgery for stage IIIC or IV ovarian cancer were included in the study. The median age at diagnosis was 64 and 84.8% of women had serous carcinoma. We identified 105 women (19.7%) on a beta-blocker of whom 94 (90%) were on a cardioselective beta-blocker. Additionally, 24 women (4.5%) were on metformin, 91 (17%) on aspirin, and 128 (24%) on a statin. In univariable analysis, beta-blocker users had a median overall survival of 29 months vs 35 months among non-users (hazard ratio HR = 1.52, p = 0.007). After adjustment for important demographic, clinical, and histopathologic factors, as well as use of other common medications, beta-blocker use remain associated with an increased hazard of death (adjusted HR 1.57, p = 0.006). CONCLUSION: In this retrospective study, we found that patients identified as being on a beta-blocker at the time of surgery had worse overall survival and greater risk of death when compared to those patients not on betablockers. Importantly, 90% of patients on beta-blockers were identified as being on a cardioselective beta-blocker.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gonzalez R, Gockley AA, Melamed A, et al. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 32222327. doi:10.1016/j.ygyno.2020.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。